RT Journal Article
SR Electronic
T1 Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 1601923
DO 10.1183/13993003.01923-2016
VO 49
IS 6
A1 Damien Viglino
A1 Ingrid Jullian-Desayes
A1 Mélanie Minoves
A1 Judith Aron-Wisnewsky
A1 Vincent Leroy
A1 Jean-Pierre Zarski
A1 Renaud Tamisier
A1 Marie Joyeux-Faure
A1 Jean-Louis Pépin
YR 2017
UL http://erj.ersjournals.com/content/49/6/1601923.abstract
AB Nonalcoholic fatty liver disease (NAFLD) is independently linked to cardiometabolic morbidity and mortality. Low-grade inflammation, oxidative stress and ectopic fat, common features of chronic obstructive pulmonary disease (COPD), might contribute to the development of NAFLD.We aimed to investigate the prevalence of NAFLD and to evaluate the relationship between various types of liver damage and COPD severity, comorbidities and circulating inflammatory cytokines. Validated noninvasive tests (FibroMax: SteatoTest, NashTest and FibroTest) were used to assess steatosis, nonalcoholic steatohepatitis (NASH) and liver fibrosis. Patients underwent an objective assessment of COPD comorbidities, including sleep studies. Biological parameters included a complete lipid profile and inflammatory markers.In COPD patients the prevalence of steatosis, NASH and fibrosis were 41.4%, 36.9% and 61.3%, respectively. In multivariate analysis, SteatoTest and FibroTest were significantly associated with sex, body mass index (BMI), untreated sleep apnoea and insulin resistance, and, in addition, COPD Global Initiative for Chronic Obstructive Lung Disease stage for SteatoTest. Patients with steatosis had higher tumour necrosis factor-α levels and those with NASH or a combination of liver damage types had raised leptin levels after adjustment for age, sex and BMI.We concluded that NAFLD is highly prevalent in COPD and might contribute to cardiometabolic comorbidities.Nonalcoholic fatty liver disease is highly prevalent in COPD patients and may contribute to comorbidities http://ow.ly/cH2h309yOlM